公开(公告)号：US10072344B2

公开(公告)日：2018-09-11

申请号：US14409144

申请日：2013-06-25

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： David Scheiner ,  Jacob Karni ,  Raymond A George ,  Gabriel Seiden

IPC: C25B9/00 ,  C25B15/00 ,  B01J8/06 ,  B01J19/24 ,  C25B9/18 ,  F28F21/04 ,  F28D7/06 ,  F28D7/10 ,  F28D7/12

CPC classification number: C25B15/00 ,  B01J8/067 ,  B01J19/248 ,  B01J2219/00078 ,  B01J2219/00081 ,  B01J2219/00085 ,  B01J2219/00135 ,  B01J2219/00155 ,  B01J2219/00186 ,  C25B9/00 ,  C25B9/18 ,  F28D7/06 ,  F28D7/106 ,  F28D7/12 ,  F28F21/04

Abstract: A reactor is provided which comprises: a plurality of reaction units located within a reaction zone, each of the reaction units being adapted to enable carrying out a chemical reaction of one or more raw gases (e.g. at least one of CO2 and H20); ingress means to allow introduction of the one or more raw gases into the reaction zone and to allow distributing the incoming gas to the plurality of reaction units; egress means to allow exit of reaction products from the reaction zone; and a heating system. The reaction units extend essentially along a longitudinal axis of the reaction zone and are arranged in a spaced-apart relationship along a lateral axis of the reaction zone. The heating system comprises a plurality of heating sources extending along the reaction zone, thereby providing at least a part of the energy to carry out the reaction process within the reaction units.

公开(公告)号：US10072044B2

公开(公告)日：2018-09-11

申请号：US15180031

申请日：2016-06-12

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Schwartz-Eisenbach ,  Matityahu Fridkin ,  Michal Cardon-Yaakov

IPC: A61K9/00 ,  A61K38/00 ,  C07K7/06 ,  C07K7/64

CPC classification number: C07K7/06 ,  A61K9/0053 ,  A61K38/00 ,  C07K7/64

Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.

公开(公告)号：US10053712B2

公开(公告)日：2018-08-21

申请号：US15101097

申请日：2014-12-10

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Arren Bar-Even ,  Ron Milo ,  Elad Noor ,  Lior Zelcbuch

IPC: C12P7/40 ,  C12N1/20 ,  C12N9/10 ,  C12N15/52 ,  C12P5/00 ,  C12P5/02 ,  C12P7/06 ,  C12P7/16 ,  C12P7/26 ,  C12P7/64

CPC classification number: C12P7/40 ,  C12N1/20 ,  C12N9/1029 ,  C12N15/52 ,  C12P5/007 ,  C12P5/023 ,  C12P5/026 ,  C12P7/06 ,  C12P7/16 ,  C12P7/26 ,  C12P7/649 ,  C12Y203/01054 ,  Y02E50/17 ,  Y02E50/343

Abstract: An isolated microorganism is disclosed being genetically modified to express pyruvate formate lyase (PFL) or 2-ketobutyrate formate lyase, wherein acetyl-CoA of the microorganism is converted to pyruvate in the presence of formate in a single step reaction, wherein the net flux of the reaction is in the direction of pyruvate synthesis.Uses of the microorganism and products comprising same are also disclosed.

公开(公告)号：US20180223302A1

公开(公告)日：2018-08-09

申请号：US15737558

申请日：2016-06-22

Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. ,  Yeda Research and Development Co. Ltd., at the Weizmann Institute of Science

Inventor： Arren BAR-EVEN ,  Tobias ERB ,  Steffen LINDNER ,  Philippe MARLIERE ,  Dan S. TAWFIK

IPC: C12N15/82

CPC classification number: C12N15/8269 ,  C12N15/8261 ,  Y02A40/146

Abstract: The present invention relates to an organism, a tissue, a cell or an organelle expressing enzymes which allow the conversion of 2-phosphoglycolate (2-PG; also known as glycolate 2-phosphate) into an intermediate compound of the Calvin-Benson-Bassham Cycle (CBBC) without releasing CO2. The organism, tissue, cell or organelle of the invention may be genetically engineered, transgenic and/or transplastomic so as to express at least one enzyme which is involved in this conversion. The present invention further relates to an organism, tissue, cell or organelle which comprises/expresses at least one enzyme which is involved in this conversion. The present invention further relates to a method for producing an organism, tissue, cell or organelle of the invention. The present invention further relates to a method of enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2. The present invention further relates to the use of an organism, tissue, cell or organelle of the invention for enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2.

公开(公告)号：US10040868B2

公开(公告)日：2018-08-07

申请号：US15328036

申请日：2014-07-24

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Moran Grossman ,  Nir Ben-Chetrit

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/40 ,  A61K45/06 ,  A61K33/24

Abstract: An article of manufacture is disclosed which comprises at least two active agents, wherein a first of the two active agents comprises an anti-cancer agent or an antifibrotic agent and a second of the at least two active agents downregulates the activity and/or expression of lysyl-oxidase like protein-2 (LOXL-2) and which is capable of altering the structure of the extracellular matrix.

公开(公告)号：US20180207249A1

公开(公告)日：2018-07-26

申请号：US15856863

申请日：2017-12-28

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Michal EISENBACH-SCHWARTZ ,  Jonathan KIPNIS

IPC: A61K39/00 ,  A61K39/39

CPC classification number: A61K39/0005 ,  A61K39/0007 ,  A61K39/39

Abstract: Copolymer 1, a Copolymer 1-related peptide, a Copolymer 1-related polypeptide; and T cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions.

公开(公告)号：US10017574B2

公开(公告)日：2018-07-10

申请号：US15147178

申请日：2016-05-05

Applicant: Yeda Research and Development Co. Ltd. ,  Victor Chang Cardiac Research Institute

Inventor： Eldad Tzahor ,  Gabriele Matteo D'Uva ,  Rachel Sarig ,  Alla Aharonov ,  Richard Paul Harvey ,  Kfir Baruch Umansky

IPC: A61K38/18 ,  A61K31/7115 ,  C07K16/28 ,  A61K39/395 ,  G01N33/50 ,  A61K38/17 ,  A61K9/00

CPC classification number: G01N33/5023 ,  A61K9/00 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/7115 ,  A61K38/1709 ,  A61K38/1825 ,  A61K38/1883 ,  G01N33/5061 ,  A61K2300/00

Abstract: A method of potentiating cardiac regeneration with neuregulin treatment in a subject in need thereof. The method comprising administering to the subject a therapeutic effective amount of an agent which upregulates activity or expression of ErbB-2, thereby potentiating cardiac regeneration with neuregulin treatment.

公开(公告)号：US20180161300A1

公开(公告)日：2018-06-14

申请号：US15571071

申请日：2016-05-10

Applicant: Yeda Research And Development Co. Ltd.

Inventor： Ayelet EREZ ,  Shiran RABINOVICH ,  Alon SILBERMAN ,  Shani AGRON

IPC: A61K31/216 ,  A61P35/00 ,  A61K31/713 ,  A61K31/513 ,  C12N15/113 ,  A61K45/06

CPC classification number: A61K31/216 ,  A61K31/198 ,  A61K31/513 ,  A61K31/713 ,  A61K45/06 ,  A61P35/00 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/531

Abstract: Provided are methods, pharmaceutical compositions and kits for treating cancer in a subject in need thereof, by administering to the subject a therapeutically effective amount of an agent which downregulates a mitochondrial aspartate-dependent pyrimidine synthesis, thereby treating the cancer.

公开(公告)号：US20180111999A1

公开(公告)日：2018-04-26

申请号：US15821678

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/02 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K31/404 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US20180111998A1

公开(公告)日：2018-04-26

申请号：US15821672

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K31/404 ,  A61K39/395 ,  A61K38/20 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.